For advanced G/GEJ cancer, first-line treatment mainly involves platinum-based chemotherapy using a combination of two or three drugs (trastuzumab is given to patients whose tumor is human epidermal growth factor receptor-2 (HER2) positive), but the overall survival (OS) is disappointing, since the maximum OS time has been reported to be 13.8 months [6–10]. This evidence concerns the gene ERBB2 and neoplasm.